We performed an economic analysis of data from 180 women in a clinical trial of conventional-dose chemotherapy vs high-dose chemotherapy plus stem-cell transplantation for metastatic breast cancer responding to first-line chemotherapy. Data on resource use, including hospitalizations, medical procedures, medications, and diagnostic tests, were abstracted from subjects' clinical trial records. Resources were valued using the Medicare Fee Schedule for inpatient costs at one academic medical center and average wholesale prices for medications. Monthly costs were calculated and stratified by treatment group and clinical phase. Mean follow-up was 690 days in the transplantation group and 758 days in the conventional-dose chemotherapy group. Subjects in the transplantation group were hospitalized for more days (28.6 vs 17.8, P ¼ 0.0041) and incurred higher costs ($84 055 vs $28 169) than subjects receiving conventional-dose chemotherapy, with a mean difference of $55 886 (95% CI, $47 298-$63 666). Sensitivity analyses resulted in cost differences between the treatment groups from $36 528 to $75 531. High-dose chemotherapy plus stem-cell transplantation resulted in substantial additional morbidity and costs at no improvement in survival. Neither the survival results nor the economic findings support the use of this procedure outside of the clinical trial setting. Bone Marrow Transplantation (2003Transplantation ( ) 31, 205-210. doi:10.1038 Keywords: breast neoplasms; clinical trial; comparative study; costs and cost analysis; female; hematopoietic stem-cell transplantation; human; neoplasm metastasis During the late 1980s, women with metastatic breast cancer increasingly requested high-dose chemotherapy and bone marrow transplantation for treatment of their disease. Demand was fueled in part by several small studies that reported improved survival from this aggressive but expensive therapy, despite concurrent reports of higher toxicity and transplant-related mortality.
rative study; costs and cost analysis; female; hematopoietic stem-cell transplantation; human; neoplasm metastasis During the late 1980s, women with metastatic breast cancer increasingly requested high-dose chemotherapy and bone marrow transplantation for treatment of their disease. Demand was fueled in part by several small studies that reported improved survival from this aggressive but expensive therapy, despite concurrent reports of higher toxicity and transplant-related mortality. [1] [2] [3] [4] [5] Use of the new therapy outside of clinical trials became especially controversial in the United States (where it was more prevalent), because insurers were reluctant to pay for the treatment in the absence of data comparing its efficacy with more conventional chemotherapy regimens. 1, 6 The dilemma of when to provide high-cost experimental therapies to patients with terminal illnesses is a difficult one. 7, 8 In patients with metastatic breast cancer, the absence of clinical trial data comparing bone marrow transplantation to conventional chemotherapy made such decisions even more difficult and emotionally charged. It was in this environment that the Philadelphia Bone Marrow Transplant Group sought to compare survival associated with high-dose chemotherapy plus stem-cell transplantation vs conventional-dose chemotherapy in women with metastatic breast cancer. Because of the anticipated high costs of the experimental therapy, resource use and costs were included as secondary end points of the study.
The clinical investigators found no significant differences in survival between patients treated with high-dose chemotherapy and stem-cell transplantation and patients treated with standard chemotherapy. 9 The results of the economic analysis are critical to our interpretation of the clinical data, because the resources required by study subjects reflect the relative toxicity of the therapies.
Patients and methods

Overview of the clinical trial
The clinical trial enrolled women aged 18-60 years who had metastatic breast cancer, adequate renal and hepatic function, and normal ventricular ejection fraction. Patients who had undergone adjuvant chemotherapy following surgical treatment of the primary tumor within 6 months of enrollment were excluded. Enrollment took place from December 1990 to December 1997. Complete inclusion and exclusion criteria have been reported previously. 9 All subjects received induction chemotherapy consisting of either doxorubicin, cyclophosphamide, and fluorouracil or cyclophosphamide, methotrexate, and fluorouracil. Subjects who had a complete response (defined as no evidence of disease), a partial response (defined as X50% reduction in the size of all tumors in 450% of all involved organ sites), or a partial response restricted to bone were randomized to one of two treatment groups. Patients in the transplantation group were treated with a regimen of highdose cyclophosphamide, carboplatin, and thiotepa for 4 days prior to hematopoietic stem-cell transplantation. Stem cells were infused approximately 48 h after the completion of chemotherapy. Patients in the conventional chemotherapy group were treated with standard outpatient doses of cyclophosphamide, methotrexate, and fluorouracil. These treatments continued until there was a treatmentlimiting toxic effect, disease progression, or completion of 24 cycles. The complete clinical protocol has been described previously. 9 
Data collection
Clinical trial records and oncology department flow sheets (hereafter termed study records) for all patients participating in the trial were sent to the study coordinating center in Philadelphia. Resource use data were not captured explicitly in the pages of the clinical case report form; however, study records provided extensive information regarding patients' clinical experiences. A single reviewer abstracted these records to document the resources used by each patient. Data were recorded as text, Current Procedural Terminology (CPT) codes, or International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The reviewer also recorded the date of service for each data point. A second reviewer then verified the data. Captured resources included hospitalizations, medical procedures, medications, diagnostic and laboratory tests, and physician services (from both inpatient and outpatient visits). Resource use was assessed from the time of randomization until death, end of followup, or final study record.
For the purpose of this analysis, each subject's course of treatment was divided into the following four phases: randomization, treatment, progression, and remission. The randomization phase consisted of the time between randomization and the first day of treatment. The treatment phase for subjects receiving conventional-dose chemotherapy began on the first day of therapy and continued through the final treatment cycle for up to 24 cycles. For subjects in the transplantation group, the treatment phase was subdivided into an initial inpatient treatment phase and a postdischarge treatment phase that continued until 1 year after transplantation. The remission phase for both groups could begin immediately after the treatment phase and continue until the end of follow-up or time of disease progression. The progression phase could begin at any time following the treatment phase and then continue until death or the end of the study period.
Using the clinical phases described above, we grouped subjects into one of three clinical trajectories. Subjects in trajectory 1 underwent randomization, treatment, remission, and progression before the end of the study. Patients in trajectory 2 underwent randomization and treatment, and proceeded immediately to the progression phase. Finally, patients in trajectory 3 underwent randomization and treatment, and continued in the remission phase until the study's end.
Valuation of resource use
Direct medical costs were valued from the societal perspective. For both treatment arms, daily costs for inpatient care (less the costs of drugs, laboratory tests, and procedures) were assigned for all inpatient days according to each subject's length of stay. Daily costs for inpatient care were estimated using the cost accounting system at a single academic medical center as follows: For transplantation hospitalizations, the daily inpatient cost was estimated from the mean daily cost of hospitalization for stem-cell transplantation. For all other hospitalizations, the daily inpatient cost was estimated from the mean daily cost of hospitalization for neutropenic fever. Costs for inpatient and outpatient laboratory tests and physician fees were estimated using relative value units and the 1998 Medicare Fee Schedule.
Medication costs were estimated using the 1998 average wholesale price for each drug. 10 For the transplantation group, costs of chemotherapeutic agents were assigned to the day of the transplantation and were included in the estimation of inpatient costs. The costs of chemotherapeutic agents for the conventional-dose chemotherapy group were based on the number of cycles received by each subject and were included in the estimation of outpatient costs. The costs of inpatient and outpatient medications not included in the study protocol were estimated using dosage and duration information collected from the study records. In approximately 2% of cases, the start date or stop date for a medication was not available. For these cases, we assumed a treatment duration of 14 days for drugs used to treat acute conditions. For drugs used to treat chronic conditions, we assumed that patients began the medication on the date it was recorded in the medical record and continued it until death or termination of follow-up. An exception was made when the duration for paclitaxel or docetaxel was missing. In these cases, we assumed that subjects received six treatment cycles.
Statistical analysis
Monthly costs for inpatient care, outpatient care, and nonstudy medications were calculated for each of the four clinical phases for subjects with complete data. If subjects were missing all costs for any month, the median costs for each clinical phase, clinical trajectory, and treatment group for that month were used to impute missing costs. Costs were then summed across clinical phases to calculate total costs for subjects in each clinical trajectory. Mean total costs for both treatment groups were calculated by summing total costs for subjects across all trajectories and dividing by the total number of subjects in both treatment groups. Costs incurred beyond 1 year of followup were discounted at 3% per year.
Mean costs by treatment group, clinical phase, and clinical trajectory were calculated. Sensitivity analyses were undertaken to assess variation in mean estimates resulting from changes in costing methods. First, the discount rate was varied from 1 to 5%. Second, base-case estimates of hospital costs were increased and decreased by 50% for both treatment groups. Third, the effects of increasing and decreasing the number of cycles of paclitaxel and docetaxel therapy from 3 to 12 cycles were evaluated for patients treated with these medications. Patients who died during the study period were included in the denominator for calculations of mean costs per treatment group and mean costs per clinical trajectory.
Subject characteristics for both treatment groups were summarized using descriptive statistics. Data were analyzed using the SAS 8.1 statistical software package (SAS Institute, Cary, NC, USA). Continuously distributed variables were compared using t-tests, and categorical variables were compared using w 2 tests. We used the nonparametric bootstrap method to assess differences in mean costs between groups, and we used the bias-adjusted percentile method to compute 95% confidence intervals (CIs). All costs are reported in 1998 US dollars.
Results
Summary of clinical trial results
A total of 199 subjects were randomized in the clinical trial. In all, 15 patients were excluded from the clinical analysis: nine were excluded because they did not respond to induction chemotherapy, three were estrogen-receptor positive but had not received prior hormone therapy or had no visceral disease, two experienced disease progression prior to randomization, and one had insufficient data for evaluation. Among the 184 subjects included in the primary analysis, 101 were assigned to stem-cell transplantation and 83 were assigned to conventional-dose chemotherapy. The 3-year survival rate was 33% and median survival was 25 months. In the transplantation group, the 3-year survival rate was 32% and median survival was 24 months, compared with a 3-year survival rate of 38% and a median survival time of 26 months for subjects in the conventional-dose chemotherapy group (P ¼ 0.23 for stratification by response to induction chemotherapy). 8 In one subgroup analysis, subjects aged 442 years who were treated with conventional-dose chemotherapy appeared to have a survival advantage. In addition, subjects who were in complete remission at the time of randomization consistently had a higher survival rate, but there was no between-group treatment difference for this subset of patients.
There was also no significant difference in time to progression between the two treatment groups. For subjects in the transplantation group, the 3-year rate of progression-free survival was 6% and the median time to progression was 9.6 months. For patients in the conventional-dose chemotherapy group, the 3-year rate of progression-free survival was 12% and the median time to progression was 9.0 months (P ¼ 0.31 for stratification by response to induction chemotherapy). 9 Again, subjects in complete remission at the time of randomization did better than patients in partial remission.
Finally, although treatment-related mortality was extremely rare (one treatment-related death in the transplantation group and zero in the conventional chemotherapy group), the incidence of moderate and severe adverse effects (eg, leukopenia, thrombocytopenia, anemia) was higher in the transplantation group. 9 
Economic analysis cohort
The economic analysis was based on data from 180 randomized patients. The analysis excluded the 15 patients who were not included in the primary clinical analysis and another four patients for whom there were insufficient resource use data. Nine patients randomized to the conventional-dose chemotherapy group underwent transplantation during the study-three during the treatment phase, three during the remission phase, and three during the progression phase. Patients in the two treatment groups were well-matched with respect to age and length of followup ( Table 1) . As mentioned above, no clinical difference was detected between the treatment arms; therefore, there was no survival advantage associated with either treatment.
A greater proportion of subjects receiving conventionaldose chemotherapy followed a type 1 clinical trajectory (randomization, treatment, remission, progression), whereas a greater proportion of subjects undergoing transplantation followed a type 2 trajectory (randomization, treatment, progression) ( Table 1) . Approximately equal proportions of transplantation and conventionaldose chemotherapy patients followed a type 3 clinical trajectory (randomization, treatment, remission).
Resource use
During the study period, subjects in the transplantation group accumulated more inpatient days than subjects in the conventional-dose chemotherapy group (28.6 vs 17.8, P ¼ 0.0041). Also, the mean length of stay per hospitalization was greater for transplant patients (21.9 days vs 15.2 days, P ¼ 0.0248). Although the number of procedures per hospital day was not significantly different between groups (5.2 in the transplantation group vs 3.9 in the conventionaldose chemotherapy group, P ¼ 0.2223), transplant patients had a significantly greater number of procedures during each outpatient visit (4.2 vs 3.5, Po0.0001).
Medical costs
We calculated inpatient, outpatient, and nonstudy medication costs for subjects in both treatment arms. Overall, mean total costs were higher ($84 055 vs $28 169) in the transplantation group than in the conventional chemotherapy group (Table 2 ). The mean cost difference between the therapies was $55 886 (95% CI, $47 298-$63 666). Mean inpatient costs were $52 448 higher (95% CI, $44 851-$59 465) for transplant patients, and nonstudy medication costs were $10 898 higher (95% CI, 9330-$13 065) compared to subjects receiving conventional chemotherapy. Mean outpatient costs were $7460 higher (95% CI, $4656-$8190) for patients receiving conventional chemotherapy (Table 2) .
We also calculated costs by clinical trajectory. In the transplantation group, type 1 patients were most costly on average ($93 105). In the conventional chemotherapy group, type 3 patients were most costly ($35 555) ( Table 2 ). Type 3 patients in both treatment groups had higher outpatient costs than type 1 or type 2 patients.
We also examined costs according to clinical phase (ie, randomization, treatment, postdischarge, remission, and progression). Among patients in both treatment groups, total costs were highest for the treatment phase (Table 3) . During the remission phase, mean costs among patients in the conventional-dose chemotherapy group were higher than for patients in the transplantation group ($6535 vs $2906). The majority of these costs were attributable to four subjects in the conventional-dose chemotherapy group who were hospitalized, three of whom underwent stem-cell transplantation.
Sensitivity analyses
We conducted several sensitivity analyses to test the robustness of our findings. The discount rate was varied from 3% to both 1 and 5%. This exerted little influence on the mean difference in costs, which ranged from $56 005 to $56 046. Hospital costs also were increased and decreased by 50%. In these analyses, the mean difference in total costs ranged from $36 528 to $75 531. Finally, we varied the number of cycles of paclitaxel and docetaxel therapies that subjects were assumed to have received. As we increased the number of cycles by three, mean total costs rose by $124 in the transplantation group and $364 in the conventional-dose chemotherapy group. This occurred because a greater proportion of patients in the conventional-dose chemotherapy group was treated with paclitaxel or docetaxel.
Discussion
We found that the incremental cost of high-dose chemotherapy plus stem-cell transplantation as compared to conventional-dose chemotherapy was approximately $56 000 per patient. Most of the cost difference was attributable to the $52 448 differential in the cost of inpatient care. As expected, majority of costs in the transplantation group were incurred in the hospital, and majority of costs in the conventional-dose chemotherapy group were incurred in the outpatient setting. Medication costs were approximately $11 000 higher in the transplantation group, and outpatient costs were approximately $7500 higher in the conventional-dose chemotherapy group. Overall treatment costs differed by clinical trajectory, and the rankings were not consistent between treatment strategies. When cost differences were relatively small, differences could easily be attributed to chance because of the variability in costs and small patient samples. However, cost differences that were more apparent deserve explanation. For example, outpatient costs for type 3 patients randomized to the conventional-dose chemotherapy group were substantially higher than outpatient costs for types 1 and 2 patients. Almost all of the type 3 patients completed 24 cycles of treatment (spending more time in the treatment phase), thus, acquiring more costs associated with administering and monitoring chemotherapy. Type 2 patients, however, experienced disease progression prior to the completion of the treatment phase. Type 1 patients had shorter treatment durations than type 3 patients, because only about half of them completed 24 cycles of treatment. The mean cost for type 3 patients during the treatment phase was $18 125, compared to $7225 for type 1 patients and $6096 for type 2 patients.
Implications
Timely completion of clinical trials can have profound implications for physician and patient decision making, as well as important economic implications for society. Since many patients and their physicians were reluctant to undergo randomization in this clinical trial, patient accrual was slow, at less than six patients per month, for the first 3 1/2 years of this 7-year-long trial. Had this rate been doubled, the trial could have been terminated 3 years earlier. Slow enrollment lengthened the period during which treatment decisions were based on inconclusive evidence from small studies. Numerous women underwent a treatment that was not only more costly and resourceintensive, but also resulted in greater morbidity. From 1989 to 1995, more than 10 000 women with breast cancer underwent stem-cell transplantation in North America alone. 6 In this analysis, we were able to quantify the additional economic burden associated with transplantation. Assuming that 1000 transplantation procedures per year were performed in North America outside of the clinical trial setting during the years of the trial reported here, society could have saved approximately $168 million by reducing the number of unnecessary transplantation procedures performed during this period.
In this pivotal trial of a novel therapeutic approach to advanced breast cancer, economic evaluation served to quantify the economic burden associated with both treatment arms and to provide additional information on the clinical trajectories of patients with this disease. The economic evaluation created no additional data collection burden for site investigators while yielding important secondary results for the study. With small incremental effort to improve collection of resource use data in cancer clinical trials, the reliability of economic data can be improved beyond even this effort.
Limitations
Collection of resource use data from subjects' clinical trial records may have resulted in underestimation of treatment costs, perhaps most extensively for the progression phase of treatment. Patients in this phase were no longer on the study after reaching the primary end point, although data were captured for a subset of these patients. Data for these patients may have been missing because the patients did not receive healthcare services, because the data were not recorded in the oncology department flow sheets, or because flow sheets were missing. Also, we assigned costs to resources used in the protocol treatment and procedures performed during inpatient stays. Itemized accounts of other resources used during inpatient stays were not included in cost estimates for hospitalizations. Instead, we assumed that patients incurred equal costs for each hospital day. Accordingly, variation in costs between patients was not tracked, although we do not expect that this affected the mean cost estimates reported here. In addition, resource costs were estimated in this study rather than directly observed. The cost of a hospital stay, for example, was estimated from one US teaching hospital's cost accounting system. While the cost estimates may not be representative of all centers participating in the study, the results of the sensitivity analyses suggest that our findings are robust even when specific cost assumptions vary.
Finally, costs for home care services, hospice care, and alternative medical therapies were not considered in the analysis because they were not recorded.
Conclusion
For patients with metastatic breast cancer, high-dose chemotherapy and stem-cell transplantation resulted in substantial additional morbidity and economic costs at no improvement in survival. Neither the survival results nor the economic findings support the use of high-dose chemotherapy plus stem-cell transplantation outside of the clinical trial setting.
